Compare SKIL & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SKIL | RNXT |
|---|---|---|
| Founded | 1998 | 2012 |
| Country | United States | United States |
| Employees | 2247 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.2M | 38.8M |
| IPO Year | N/A | 2021 |
| Metric | SKIL | RNXT |
|---|---|---|
| Price | $6.18 | $0.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.25 |
| AVG Volume (30 Days) | 132.2K | ★ 220.3K |
| Earning Date | 04-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,123,000.00 |
| Revenue This Year | $0.11 | $194.66 |
| Revenue Next Year | N/A | $279.78 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 2511.63 |
| 52 Week Low | $3.43 | $0.70 |
| 52 Week High | $18.45 | $1.45 |
| Indicator | SKIL | RNXT |
|---|---|---|
| Relative Strength Index (RSI) | 43.36 | 44.67 |
| Support Level | $4.92 | $0.81 |
| Resistance Level | $8.34 | $0.98 |
| Average True Range (ATR) | 0.68 | 0.05 |
| MACD | -0.10 | -0.01 |
| Stochastic Oscillator | 30.00 | 25.06 |
Skillsoft Corp is a leader in corporate digital learning. The company's segments include Talent Development Solutions and Global Knowledge. Talent Development Solutions brings a foundation of products and customers. TDS enterprise-grade solution serves customers and employees world-wide. TDS Learner is a world-renowned consumer-scale and experiential learning platform that serves learners internationally. The Global Knowledge segment is centered around instructor-led training, or live learning, with face-to-face delivery by experienced trainers, both in-person and virtually.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site (known as intra-arterial, or IA delivery) to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.